International study for treatment of childhood relapsed ALL (2010) with standard therapy, systematic integration of new agents, and establishment of standardized diagnostic and research.
FP7-HEALTH-2011 – Grant Agreement ID 278514
1 October 2011 to 30 September 2017
Survival of children with acute lymphoblastic leukaemia (ALL) has significantly improved over the past decades. Nevertheless, relapse of the disease remains a leading cause of mortality in childhood cancer. Given the rarity of childhood relapsed ALL, only a large international cooperative group can recruit sufficient patients for prospective studies with specific questions in biological subgroups. Under the umbrella of the International BFM Study Group and with the support of the EU FP7 Program, the relevant study groups have formed the worldwide largest international study for children and adolescents with relapsed ALL (in 2010), lntReALL 2010. The consortium has developed a platform for diagnostics, optimized standard treatment with innovative elements, and translational research for improvement of survival of the affected children and better understanding of this life-threatening disease. GenomeScan performed Next Generation Sequencing (NGS) analyses of a candidate gene panel established by the consortium, to detect alterations relevant for prognosis and suitable for targeted treatment options.
This project has received funding from the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement No 278514.